New lipid lowering drugs and new effects of old drugs.
Old lipid acting drugs (fibrates, resins and niacin) continue to demonstrate morbidity and mortality benefits with variable efficacy and safety. Controlled trials have provided efficacy and safety data that support the use of statins as the first choice in the treatment and prevention of atherosclerosis. Knowledge of old and new mechanisms of action, optimal doses, pharmacokinetic behavior and drug interactions improve the safety and effectiveness of these hypolipidemic agents.
Dujovne
C A
CA
Arteriosclerosis and Metabolic Clinic, Kansas University Hospital, Kansas City 66160-7374, USA.
D000924:Anticholesteremic Agents; D001161:Arteriosclerosis / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D009525:Niacin / Q000627:therapeutic use; D011341:Probucol / Q000627:therapeutic use; D012116:Resins, Plant / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D012116:Resins, Plant; D009525:Niacin; D011341:Probucol